Roche Holding AG
SIX:RO

Watchlist Manager
Roche Holding AG Logo
Roche Holding AG
SIX:RO
Watchlist
Price: 355.8 CHF -0.06%
Market Cap: CHf245.7B

Relative Value

The Relative Value of one RO stock under the Base Case scenario is hidden CHF. Compared to the current market price of 355.8 CHF, Roche Holding AG is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RO Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

RO Competitors Multiples
Roche Holding AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Roche Holding AG
SIX:RO
275.2B CHF 4.5 29.2 12.4 14.5
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.4 37.2 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
528.2B USD 5.6 19.7 13.8 16.9
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.9 30.3 19.7 28.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 5.7 17.3 12 14
CH
Novartis AG
SIX:NOVN
220.9B CHF 5 19.4 15.6 20.1
US
Merck & Co Inc
NYSE:MRK
269.2B USD 4.2 14.1 10 11.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
145.4B USD 2.3 14.8 7.5 10.3
FR
Sanofi SA
PAR:SAN
96.2B EUR 1.4 7 6.4 6.4
P/E Multiple
Earnings Growth PEG
CH
Roche Holding AG
SIX:RO
Average P/E: 23
29.2
29%
1
US
Eli Lilly and Co
NYSE:LLY
55.4
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
6%
3.3
UK
AstraZeneca PLC
LSE:AZN
30.3
37%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
17.3
3%
5.8
CH
Novartis AG
SIX:NOVN
19.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.1
15%
0.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
FR
Sanofi SA
PAR:SAN
7
26%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
Roche Holding AG
SIX:RO
Average EV/EBITDA: 393.3
12.4
5%
2.5
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.8
-1%
N/A
UK
AstraZeneca PLC
LSE:AZN
19.7
10%
2
DK
Novo Nordisk A/S
CSE:NOVO B
12
1%
12
CH
Novartis AG
SIX:NOVN
15.6
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
FR
Sanofi SA
PAR:SAN
6.4
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
Roche Holding AG
SIX:RO
Average EV/EBIT: 1 702.7
14.5
6%
2.4
US
Eli Lilly and Co
NYSE:LLY
39.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.9
4%
4.2
UK
AstraZeneca PLC
LSE:AZN
28.9
23%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14
0%
N/A
CH
Novartis AG
SIX:NOVN
20.1
12%
1.7
US
Merck & Co Inc
NYSE:MRK
11.8
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5
FR
Sanofi SA
PAR:SAN
6.4
15%
0.4